AIDS Memorial Quilt Should Be Displayed In Entirety To Raise Profile, Understanding Of HIV/AIDS, Letter To Editor Says

The Atlanta-based Names Project Foundation — which is involved in a lawsuit over the AIDS Memorial Quilt with Cleve Jones, who started the quilt in 1987 and served as its spokesperson for 15 years — should “let go” of the quilt and “assist in displaying it in its entirety” to raise the profile and understanding of HIV/AIDS in the U.S., Jerry Clark, founder and CEO of the not-for-profit We Care Minnesota, writes in a New York Times letter to the editor in response to a Jan. 31 Times article (Clark, New York Times, 2/4). Jones and NPF in December 2005 reached an agreement on the issue of returning a portion of the quilt to San Francisco. Under the agreement, Jones will receive 35 blocks of the quilt after he creates a San Francisco-based organization to oversee them. According to the agreement, Jones was required to establish a “501(c)(3) nonprofit organization that will have the name of San Francisco Bay Area Friends of the AIDS Memorial Quilt” by Dec. 31, 2006. The settlement stipulated that if the deadline was not met, the foundation would be “relieved of any obligation to supply blocks of the quilt to the nonprofit.” Jones said that he established a not-for-profit by the deadline through the San Francisco-based Tides Center, which oversees more than 200 projects. The dispute arises from the Tide Center’s Web site, which states that it is “legally and financially responsible for all Tides Center projects and activities” and that “[p]rojects are not separate entities or affiliated organizations — projects are Tides Center.” An attorney for NPF in January said Jones has not met the requirement (Kaiser Daily HIV/AIDS Report, 1/31). “If the quilt were displayed in its entirety, the country might just wake up” to the impact of HIV/AIDS, Clark writes, adding that increased funding for research and prevention efforts “would be a natural result of raising the profile and understanding of this terrible disease” (New York Times, 2/4).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

New Washington, D.C., HIV/AIDS Administration Director Pane Announces Initiatives To Fight City’s Epidemic

The director of Washington, D.C.’s Administration for HIV Policy and Programs, Gregg Pane, who replaced Marsha Martin in January, has announced plans to launch a series of “critical tasks” within the next 90 days aimed at addressing the district’s HIV/AIDS epidemic, the AP/Washington Examiner reports (AP/Washington Examiner, 2/4). District Mayor Adrian Fenty in January confirmed that he would not reappoint Martin as director of the city’s HIV/AIDS administration. Martin’s 16-month tenure as director of the HIV administration earned mixed reviews. Although she was lauded for increasing awareness about HIV/AIDS in the district, she was criticized for her method of collaborating and coordinating with the HIV/AIDS community (Kaiser Daily HIV/AIDS Report, 1/4). Pane’s HIV/AIDS initiatives include developing response and prevention plans, increasing condom distribution and enhancing HIV/AIDS case tracking, according to the AP/Examiner. Under the campaign, the administration by mid-February will distribute 250,000 condoms to 60 not-for-profits, and HIV rapid test kits will be distributed to physicians. The administration also is developing a comprehensive HIV prevention plan that will target young people, assess grant management and conduct oversight visits of the government’s service providers. In addition, Pane said that the administration plans to enter 1,200 backlogged HIV surveillance cases into city databases, which are needed to accurately record the extent of the epidemic and apply for federal grant money, the AP/Examiner reports. “I felt action was needed,” Pane said last week, adding, “We’re all saying it’s a crisis. Let’s do something. Shake it up and set some goals.” The DC Appleseed Center for Law and Justice contributed to planning the initiatives, Pane said. Appleseed Center Executive Director Walter Smith said, “My reaction is it’s a very good thing that Dr. Pane this quickly is trying to get organized and give this thing high priority, high visibility” (AP/Washington Examiner, 2/4).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Texas AG Abbott Rules That State Law Permits Prison Officials To Mandate HIV Testing Among State Prisoners

Texas Attorney General Greg Abbott (R) on Thursday ruled that state law permits the Texas Board of Criminal Justice to mandate HIV testing among inmates upon entry to state prisons, the Houston Chronicle reports (Babineck, Houston Chronicle, 2/2). The state prison system in August 2006 had proposed a change to its HIV testing policy from saying new inmates “should be tested” upon entering prison to saying they “shall be tested” unless they opt out of testing. State Sen. Rodney Ellis (D) in August 2006 asked Abbott to rule whether current state law allows mandatory HIV testing for prisoners upon entry. Ellis — who with state Rep. Yvonne Davis (D) sponsored legislation approved last year that requires inmates to be tested for HIV before departing prison — said if Abbott ruled that current law does not allow mandated entry tests, he would sponsor a bill that would include such a requirement. About 80% of inmates have agreed to take an HIV test upon entering prison since the state began its testing program, and prison system statistics show more than 38,700 inmates received HIV tests in 2005. Of those, 372 tested HIV-positive. Texas law mandates that HIV test results are confidential and that HIV-positive inmates are not separated from HIV-negative inmates. Advocates for mandatory HIV testing upon entry into the prison system say it would help prison officials properly treat HIV-positive people, would provide more accurate data on the spread of the disease and could help officials estimate how many people are becoming HIV-positive in prison. July 2006 statistics show that of 154,000 prisoners in Texas, 2,627 are HIV-positive (Kaiser Daily HIV/AIDS Report, 8/24/06). Abbott’s opinion, which leaves the decision regarding mandatory testing up to the Texas Department of Criminal Justice, says that TBCJ is “authorized to adopt a rule or policy requiring mandatory” HIV testing among “incoming offenders in both the institutional division and the state jail division.” According to TDCJ spokesperson Jason Clark, there is no indication that the department is planning to make HIV testing among incoming prisoners mandatory anytime soon. Ellis did not comment on Abbott’s ruling, the Chronicle reports (Houston Chronicle, 2/2).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

ViroPharma Receives Orphan Drug Designation For Maribavir For Cytomegalovirus Viremia And Disease Indication

ViroPharma Incorporated (Nasdaq: VPHM) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for maribavir for prevention of cytomegalovirus (CMV) viremia and disease in the populations at-risk.

The Orphan Drug Act was designed to provide incentives to companies to develop drugs that treat conditions affecting 200,000 or fewer patients annually in the U.S. and that provide a significant therapeutic advantage over existing treatments or fill an unmet medical need. Orphan drug designation entitles ViroPharma to seven years of market exclusivity in the United States upon FDA approval of maribavir, provided that the company continues to meet certain conditions established by the FDA. Other potential advantages include protocol assistance, the potential for priority review, tax credits, and other financial incentives.

“We are particularly pleased to receive orphan designation for the product from the FDA,” commented Colin Broom, M.D., ViroPharma’s chief scientific officer. “We have made excellent progress with maribavir over the last 12 months. We demonstrated in a Phase 2 clinical trial that the drug appears to be well tolerated with impressive anti-CMV activity in stem cell transplant patients, which has allowed us to initiate our international Phase 3 development program. The receipt of this designation marks one more important milestone in the development of the compound. Maribavir is an important Phase 3 drug candidate for a significant unmet medical need, and may one day provide an effective and well tolerated therapeutic alternative for patients at risk of CMV disease.”

About Maribavir

Maribavir is a potent and selective, orally bioavailable antiviral drug with a unique mechanism of action against cytomegalovirus and a favorable early clinical safety profile. It is a potent member of a new class of drugs called benzimidazole ribosides. Unlike currently available anti-CMV agents that inhibit CMV DNA polymerase, maribavir inhibits viral DNA assembly and egress of viral capsids from the nucleus of infected cells. Maribavir is also active in vitro against strains of CMV that are resistant to commonly used anti-CMV drugs.

About Cytomegalovirus

CMV is a member of the herpes virus group, which includes the viruses that cause chicken pox, mononucleosis, herpes labialis (cold sores), and herpes genitalis (genital herpes). Like other herpesviruses, CMV has the ability to remain dormant in the body for long periods of time. Human CMV infection rates average between 50% and 85% of adults in the U.S. by 40 years of age, but in healthy adults causes little to no apparent illness. However, in immunocompromised individuals including cancer patients, HIV patients, and transplant patients, and in children born with primary CMV infection, CMV can lead to serious disease or death. Patients who are immunosuppressed following hematopoietic stem cell (bone marrow) or solid organ transplantation are at high risk of CMV infection. In these patients, CMV can lead to severe conditions such as pneumonitis or hepatitis, or to complications such as acute or chronic rejection of a transplanted organ. While currently available systemic anti-CMV agents are effective against the virus, their use is limited by toxicities, most notably bone marrow suppression and renal impairment.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company’s website at http://www.viropharma.com/.

Certain statements in this press release may contain forward-looking statements that involve a number of risks and uncertainties, including those relating to our hope that maribavir may offer transplant patients a better tolerated, efficacious treatment option. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. There can be no assurance that that maribavir will ever be approved by the FDA. These factors, and other factors, including, but not limited to those described in ViroPharma’s quarterly report on Form 10-Q for the quarters ended March 31, 2006, June 30, 2006 and September 30, 2006 filed with the Securities and Exchange Commission, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

ViroPharma Incorporated
http://www.viropharma.com/

UNAIDS To Introduce HIV Testing Guidelines In India That Recommend Provider-Initiated Testing, Counseling

UNAIDS in March plans to introduce new HIV testing guidelines in India that recommend health care providers initiate testing and counseling, the Hindustan Times reports. Under the country’s current HIV testing policy, tests are provided only when people request them. Requests for HIV tests in general are low, and about one in 10 HIV-positive people in India are aware of their status, the Times reports. The new guidelines emphasize informed consent and counseling before an HIV test can be administered, according to the Times. Denis Broun, UNAIDS India coordinator, said the group does not “support mandatory testing. Testing must be confidential, include counseling and occur only with informed consent.” He added that no one will be “forced into testing, as the rules of opting out are very clear.” In addition, the new testing guidelines will “phenomenally” increase the number of people receiving HIV tests in the country, Broun said, adding that the guidelines “aim to reach the nine in 10 undiagnosed [HIV-positive] people who miss out on treatment.” However, some human rights advocates have said that India does not have the health infrastructure to provide treatment and care for the thousands of people who will test positive for HIV, the Times reports. “The government cannot test people and send them away,” Anjali Gopalan, executive director of Naz Foundation India Trust, said, adding, “India first needs to ensure proper counseling, upgrade voluntary testing and counseling centers, and set up the required facilities in states that have no health infrastructure or social security for people to fall back on.” Loon Gangte, president of the Delhi Network of Positive People, said, “Before scaling up HIV testing, the government must ensure there is no stigma and discrimination” against HIV-positive people. He added that the government “must also provide assured access to treatment and care services.” According to Broun, provider-initiated testing has increased the number of people receiving HIV tests in several East African countries, including Botswana, Malawi and Uganda (Sharma, Hindustan Times, 2/1).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Boston Globe Reports On Internal Investigation Of Global Fund Practices

The Boston Globe on Monday reported on an internal inspector general investigation into the business expense practices of the executive director of the Global Fund To Fight AIDS, Tuberculosis and Malaria. According to the Globe’s description of the investigation, which was completed in August 2006, Global Fund Executive Director Richard Feachem has “made extensive use of a little-known private bank account, spending hundreds of thousands of dollars on limousines, expensive meals, boat cruises and other expenses.” According to the Globe, a separate investigation by the World Health Organization also “raised concerns” over use of the account. Global Fund spokesperson Jon Liden said, “These expenses are reasonable and necessary for carrying out the business of the Global Fund,” adding that the report is of “extraordinarily poor quality in terms of accuracy, context and fairness. We have nothing to hide.” (Donnelly, Boston Globe, 2/5) The Global Fund in a release on Monday provided comments and clarifications on a “number of untrue or misleading statements” made in the Globe article (Global Fund release, 2/5).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Washington County Records Four Cases Of Drug-Resistant HIV

Four men in King County, Washington, have been diagnosed with a strain of HIV that is resistant to at least two types of antiretroviral drugs, and health officials on Thursday said they are concerned the strain could spread, the Seattle Times reports. According to the Times, a third antiretroviral has limited effectiveness against the strain (King, Seattle Times, 2/2). Officials said that the same genetic strain of HIV was recorded within 15 months among the men, who were diagnosed with the drug-resistant strain as soon as they tested HIV positive. The men used methamphetamine and had multiple anonymous sexual partners, including men. None of the men was known to have had sex with any of the other three, according to officials (AP/Houston Chronicle, 2/2). Some of the men’s partners have been identified, none of whom has tested positive for the resistant strain, Bob Wood, HIV/AIDS program director for the Seattle-King County Public Health Department, said. There is no information about how easily this strain might be transmitted or whether it was spread to Seattle from another city. The agency plans to distribute fliers in gay bars and bathhouses about the HIV strain, and physicians are being asked to test all newly diagnosed HIV cases for drug resistance and report them to the health department, Wood said. According to physicians, it is unlikely the drug-resistant HIV strain will cause the men to progress more rapidly to AIDS; however, once they do progress to the disease, treating them will be more difficult (Seattle Times, 2/2). Health officials as of last week had recorded 12 cases of multidrug-resistant HIV in the county, but none of the cases was as resistant to antiretrovirals as the most recent four, the AP/Chronicle reports (AP/Houston Chronicle, 2/2). About 350 to 400 new HIV cases are reported in King County annually, and about 8,000 county residents are living with the virus. Wood said the new cases should serve as an early warning because “they show there is some ongoing transmission” (Seattle Times, 2/2). Wood added, “This is mostly about behavior. Men who have sex with men need to know that drug-resistant strains can and are being transmitted and may be much less treatable” (Paulson, Seattle Post-Intelligencer, 2/2).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Bush FY 2008 Budget Proposal Would Allocate $5.4B For PEPFAR

President Bush on Monday released his $2.8 trillion fiscal year 2008 budget proposal, which would allocate $5.4 billion for the President’s Emergency Plan for AIDS Relief, the Wall Street Journal reports (Phillips, Wall Street Journal, 2/6). Bush’s budget proposal would allocate $4.2 billion for treatment, prevention and care initiatives to PEPFAR’s 15 focus countries, as well as an additional $1.2 billion for global HIV/AIDS programs, disease research and contributions to partner organizations (President’s FY 2008 budget, 2/5). Included in the PEPFAR budget, Bush has asked for $300 million for the Global Fund To Fight AIDS, Tuberculosis and Malaria and $491 million for other activities, including TB programs (PEPFAR.gov release, 2/2). In addition to the PEPFAR funding, the budget proposal would provide $300 million for the President’s Malaria Initiative and ongoing malaria programs worldwide (President’s FY 2008 budget, 2/5). The budget proposal also calls for $3 billion for the Millennium Challenge Corporation, a program meant to encourage economic and political reforms in developing countries, VOA News reports (VOA News, 2/5). Bush’s budget proposal comes a week after the House voted 286-140 to approve a $463 billion spending resolution (HJ Res 20) for FY 2007 that includes a $1.3 billion increase for PEPFAR. The resolution would bring the total for PEPFAR to $4.5 billion and would allocate $724 million for the U.S. contribution to the Global Fund. In addition, $248 million would be allocated to expand programs under PMI, an increase of $149 million. The Senate is expected to consider the bill this week (Kaiser Daily HIV/AIDS Report, 2/2). “The Global fund will need $1.4 billion from the U.S., as well as added funding from the rest of the world,” Friends of the Global Fight President Jack Valenti said, adding, “We are concerned that without additional funds, a lot of people will die. In the upcoming year, I look forward to working with the [Bush] administration and Congress to fully fund the Global Fund and the president’s programs” (Friends of the Global Fight release, 2/5).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Chinese Authorities Prevent HIV/AIDS Advocate From Coming To U.S. To Accept Award

Chinese HIV/AIDS advocate and retired physician Gao Yaojie last week was put under house arrest by Chinese authorities to prevent her from visiting the U.S. next month to accept an award from the group Vital Voices Global Partnership, the New York Times reports (Yardley, New York Times, 2/6). According to Gao’s friend and Beijing-based AIDS advocate Hu Jia, Chinese authorities from the eastern province Henan told Gao not to attend the Vital Voices awards ceremony, the AP/Washington Post reports. When Gao refused, she was put under house arrest to prevent her from traveling to Beijing to apply for a U.S. visa, Hu said. Gao’s friends and family were blocked from visiting her or were questioned before being given permission to visit, and her daughter is under police surveillance, Hu said (Olesen, AP/Washington Post, 2/4). A spokesperson for the U.S. Embassy in Beijing said the embassy had “raised the issue [of Gao's house arrest] with the Chinese Ministry of Foreign Affairs” but did not give details, according to Reuters UK (Reuters UK, 2/5). Gao in the 1990s alerted people in Henan of HIV cases that occurred through tainted blood transfusions (AP/Washington Post, 2/4). Gao also distributed material warning people of HIV and the risks of donating blood, Reuters UK reports (Reuters UK, 2/5). In addition, Gao has distributed medicine to HIV-positive people, provided cared for AIDS orphans and hosted people living with HIV/AIDS in her home. She also has written a book about the HIV/AIDS epidemic in China, the AP/Post reports (AP/Washington Post, 2/4). Chinese authorities in 2001 and 2003 prevented Gao from traveling abroad to accept awards for her work, Reuters UK reports (Reuters UK, 2/5). “We would like to believe that this is a misunderstanding because Dr. Gao has been publicly recognized by the Chinese government many times,” Wenchi Yu Perkins, Vital Voices’ human rights program director, said, adding, “We are talking to our contacts in China to understand what is happening.” Chinese Foreign Ministry spokesperson Jiang Yu on Tuesday said that she is not aware of Gao’s situation. China is a “country ruled by law” that “protect[s] the rights of all citizens,” she said, adding, “Nobody has the right to be above the law” (Olesen, AP/Forbes, 2/6).

“Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Preclinical Results Of Geovax’s AIDS Vaccines Demonstrate Potential To Protect Against Disease

GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, have reported successful results from a preclinical trial using GeoVax’s vaccines for the therapeutic treatment and prevention of Acquired Immunodeficiency Disease Syndrome (“AIDS”) in non-human primates. The data demonstrate the effectiveness of GeoVax’s DNA/MVA vaccines in controlling the Simian (“SIV”) AIDS virus through immune responses raised by the vaccines. These promising results have resulted in preliminary plans to conduct human therapeutic studies utilizing GeoVax’s vaccines.

In this trial, two monkeys were infected with the SIV AIDS virus and then placed on drug therapy. Thereafter, once early drug therapy had temporarily reduced virus levels, the monkeys were vaccinated with the SIV version of GeoVax’s DNA/MVA vaccines. Six weeks after vaccination, drug treatment was discontinued. The SIV virus levels temporarily rose in the vaccinated individuals, but were later “controlled” (reduced to much lower levels) by immune responses raised by the vaccines.

The reduction of virus levels in the blood stream of these AIDS virus-infected non-human primates has continued for more than a year to date. Vaccination with the GeoVax DNA/MVA vaccines has curtailed the development of AIDS and its associated debilitating effects, resulting in healthy, asymptomatic individuals. The monkeys have gained weight and have not required any additional drug therapy.

“The results of this trial demonstrate the long-term promise of our vaccines in treating HIV-AIDS,” said Don Hildebrand, CEO of GeoVax Labs. “Our preclinical trials, coupled with encouraging data from two ongoing human trials, help validate the science behind our vaccines and provide the impetus for accelerating the planning of Phase II human trials for our preventive vaccines.”

The ability to vaccinate those already infected with the AIDS virus, thereby inhibiting the virus’ progressive and debilitating effects, would allow individuals to fight off normal infections, live longer and maintain a more normal lifestyle. Such a vaccine, if approved for distribution, would be considerably more cost-effective and without the same side effects associated with current drug treatment programs.

The promising results from this trial have resulted in preliminary plans to conduct human therapeutic studies utilizing GeoVax’s AIDS vaccines with the hope of extending the length and quality of life in people already infected with the AIDS virus.

###

These studies were conducted at Emory University and were supported by funding from the National Institutes of Health.

Safe Harbor Statement

All statements in this news release that are not statements of historical fact are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, whether; GeoVax can develop these vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be determined to be safe for use in humans, GeoVax’s vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Companies Securities and Exchange Commission filings and reports.

Contact: Melanie Nimrodi
Financial Relations Board